• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铁螯合疗法治疗输血引起的铁过载。

Iron-chelating therapy for transfusional iron overload.

机构信息

Division of Pediatric Hematology, Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA.

出版信息

N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810.

DOI:10.1056/NEJMct1004810
PMID:21226580
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3078566/
Abstract

A 16-year-old boy with sickle cell anemia undergoes routine screening with transcranial Doppler ultrasonography to assess the risk of stroke. This examination shows an abnormally elevated blood-flow velocity in the middle cerebral artery. The hemoglobin level is 7.2 g per deciliter, the reticulocyte count is 12.5%, and the fetal hemoglobin level is 8.0%. Long-term treatment with red-cell transfusion is initiated to prevent stroke. A hematologist recommends prophylactic iron-chelating therapy.

摘要

一位 16 岁的镰状细胞贫血男孩接受经颅多普勒超声检查进行常规筛查,以评估中风风险。该检查显示大脑中动脉的血流速度异常升高。血红蛋白水平为每分升 7.2 克,网织红细胞计数为 12.5%,胎儿血红蛋白水平为 8.0%。开始进行长期红细胞输血治疗以预防中风。血液科医生建议进行预防性铁螯合治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e33/3078566/380226d2f280/nihms-272392-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e33/3078566/380226d2f280/nihms-272392-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e33/3078566/380226d2f280/nihms-272392-f0001.jpg

相似文献

1
Iron-chelating therapy for transfusional iron overload.铁螯合疗法治疗输血引起的铁过载。
N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810.
2
Iron chelation therapy for patients with sickle cell disease and iron overload.镰状细胞病和铁过载患者的铁螯合疗法。
Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806.
3
Deferasirox for managing transfusional iron overload in people with sickle cell disease.地拉罗司用于治疗镰状细胞病患者的输血性铁过载。
Cochrane Database Syst Rev. 2010 Aug 4(8):CD007477. doi: 10.1002/14651858.CD007477.pub2.
4
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.地拉罗司与去铁胺治疗镰状细胞病输血性铁过载的随机对照研究
Br J Haematol. 2007 Feb;136(3):501-8. doi: 10.1111/j.1365-2141.2006.06455.x.
5
[Pathogenesis of transfusional iron overload and iron chelation therapy].[输血性铁过载的发病机制及铁螯合疗法]
Rinsho Ketsueki. 2009 Jul;50(7):527-31.
6
[Iron overload and iron chelation therapy in transfusion-dependent patients].[输血依赖型患者的铁过载与铁螯合疗法]
Nihon Rinsho. 2008 Mar;66(3):563-8.
7
Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.比较去铁酮与去铁胺在镰状细胞病中的疗效和安全性:包括药代动力学和同时使用羟基脲的两年结果。
Am J Hematol. 2013 Dec;88(12):1068-73. doi: 10.1002/ajh.23569. Epub 2013 Sep 19.
8
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2017 Aug 15;8(8):CD007476. doi: 10.1002/14651858.CD007476.pub3.
9
The Role of Deferiprone in Iron Chelation.去铁酮在铁螯合中的作用。
N Engl J Med. 2018 Nov 29;379(22):2140-2150. doi: 10.1056/NEJMra1800219.
10
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007476. doi: 10.1002/14651858.CD007476.pub2.

引用本文的文献

1
The Efficacy and Safety of Deferasirox Monotherapy as a Second-Line Treatment in Transfusion-Dependent Thalassemia with Iron Overload.去铁胺单药作为二线治疗对依赖输血的地中海贫血合并铁过载的疗效及安全性
J Clin Med. 2025 Sep 3;14(17):6212. doi: 10.3390/jcm14176212.
2
Iron Overload Cardiomyopathy in Myelodysplastic Syndrome: A Fatal Outcome After 20 Years of Chronic Transfusions.骨髓增生异常综合征中的铁过载心肌病:20年慢性输血后的致命结局
JACC Case Rep. 2025 Aug 20;30(24):104667. doi: 10.1016/j.jaccas.2025.104667.
3
DFO-loaded PDA nanoparticles facilitated 3D stem cell spheroids for diabetic wound repair by normalizing the pathological microenvironment.

本文引用的文献

1
Controversies surrounding iron chelation therapy for MDS.有关骨髓增生异常综合征铁螯合疗法的争议。
Blood Rev. 2011 Jan;25(1):17-31. doi: 10.1016/j.blre.2010.09.003. Epub 2010 Oct 27.
2
The inherited diseases of hemoglobin are an emerging global health burden.血红蛋白遗传疾病是一个正在浮现的全球性健康负担。
Blood. 2010 Jun 3;115(22):4331-6. doi: 10.1182/blood-2010-01-251348. Epub 2010 Mar 16.
3
Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
负载去铁胺的聚多巴胺纳米颗粒通过使病理微环境正常化,促进3D干细胞球体用于糖尿病伤口修复。
Mater Today Bio. 2025 Jun 14;33:101973. doi: 10.1016/j.mtbio.2025.101973. eCollection 2025 Aug.
4
Ferroptosis: An Energetic Villain of Age-Related Macular Degeneration.铁死亡:年龄相关性黄斑变性的一个“能量反派”
Biomedicines. 2025 Apr 17;13(4):986. doi: 10.3390/biomedicines13040986.
5
The challenges of iron chelation therapy in thalassemia: how do we overcome them?地中海贫血中铁螯合疗法的挑战:我们如何克服这些挑战?
Expert Rev Hematol. 2025 Apr-May;18(5):351-357. doi: 10.1080/17474086.2025.2489562. Epub 2025 Apr 8.
6
Fluvastatin suppresses hemin-induced cell death, reactive oxygen species generation, and elevated labile iron pool.氟伐他汀可抑制血红素诱导的细胞死亡、活性氧生成及不稳定铁池升高。
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S284-S290. doi: 10.1016/j.htct.2024.09.2480. Epub 2024 Nov 7.
7
Global Trends on β-Thalassemia Research Over 10 Years: A Bibliometric Analysis.10年全球β地中海贫血研究趋势:文献计量分析
Int J Gen Med. 2024 Sep 11;17:3989-4001. doi: 10.2147/IJGM.S479493. eCollection 2024.
8
Bacterial siderophores: diversity, uptake pathways and applications.细菌铁载体:多样性、摄取途径及应用
Nat Rev Microbiol. 2025 Jan;23(1):24-40. doi: 10.1038/s41579-024-01090-6. Epub 2024 Sep 5.
9
State-of-the-Art Quantification of Liver Iron With MRI-Vendor Implementation and Available Tools.利用MRI供应商实施和现有工具对肝脏铁进行的最新量化
J Magn Reson Imaging. 2025 Mar;61(3):1110-1132. doi: 10.1002/jmri.29526. Epub 2024 Aug 12.
10
Genome-wide methylation and gene-expression analyses in thalassemia.地中海贫血症中的全基因组甲基化和基因表达分析。
Aging (Albany NY). 2024 Aug 9;16(15):11591-11605. doi: 10.18632/aging.206037.
在处于药代动力学稳态的输血依赖型铁过载β-地中海贫血患者中,地拉罗司的药代动力学、代谢和处置。
Drug Metab Dispos. 2010 May;38(5):808-16. doi: 10.1124/dmd.109.030833. Epub 2010 Jan 22.
4
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.通过铁摄入量和血清铁蛋白调整铁螯合治疗:前瞻性 EPIC 研究中 1744 例输血依赖型贫血患者应用地拉罗司。
Haematologica. 2010 Apr;95(4):557-66. doi: 10.3324/haematol.2009.014696. Epub 2009 Nov 30.
5
Guidelines for the diagnosis and management of aplastic anaemia.再生障碍性贫血诊断与治疗指南。
Br J Haematol. 2009 Oct;147(1):43-70. doi: 10.1111/j.1365-2141.2009.07842.x. Epub 2009 Aug 10.
6
Specific iron chelators determine the route of ferritin degradation.特定的铁螯合剂决定了铁蛋白的降解途径。
Blood. 2009 Nov 12;114(20):4546-51. doi: 10.1182/blood-2009-05-224188. Epub 2009 Aug 11.
7
Nutritional deficiencies in iron overloaded patients with hemoglobinopathies.血红蛋白病铁过载患者的营养缺乏
Am J Hematol. 2009 Jun;84(6):344-8. doi: 10.1002/ajh.21416.
8
High doses of deferiprone may be associated with cerebellar syndrome.高剂量的去铁酮可能与小脑综合征有关。
BMJ. 2009 Jan 22;338:a2319. doi: 10.1136/bmj.a2319.
9
Consensus statement on iron overload in myelodysplastic syndromes.骨髓增生异常综合征铁过载的共识声明。
Am J Hematol. 2008 Nov;83(11):858-61. doi: 10.1002/ajh.21269.
10
Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference.诊断与治疗先天性纯红细胞再生障碍性贫血:国际临床共识会议结果
Br J Haematol. 2008 Sep;142(6):859-76. doi: 10.1111/j.1365-2141.2008.07269.x. Epub 2008 Jul 30.